Ananda Developments says cannabinoid-based medicine will become "completely ubiquitous"
News release
by
Ananda Developments Plc
London, UK
|
June 14, 2023 03:46 AM Eastern Daylight Time
Ananda Developments (AQSE:ANA) co-founder and CEO Melissa Sturgess visits the Proactive London studio to speak with Thomas Warner about the work the cannabinoid medicine development company is doing to help develop treatments for patients suffering from complex, chronic inflammatory pain conditions.
Sturgess says that cannabinoid-based medicine will ultimately become "completely ubiquitous" and highlights the various fronts that Ananda is currently pushing forward on, including two upcoming phase II randomised controlled clinical trials.
Contact Details
Proactive UK Ltd
Proactive UK Ltd
+44 20 7989 0813
